Description
LINATAB M 5/1000 is a fixed-dose combination antidiabetic tablet containing 5 mg linagliptin (a DPP-4 inhibitor) and 1000 mg metformin hydrochloride (a biguanide), designed as an extended-release (ER) formulation for once-daily dosing with meals15. Linagliptin enhances glucose-dependent insulin secretion and reduces glucagon release by prolonging incretin hormone activity, while metformin lowers blood glucose by suppressing hepatic glucose production and improving insulin sensitivity15.
This ER version is prescribed for type 2 diabetes mellitus, particularly for patients requiring both agents, and is initiated as one tablet daily with food12. Key considerations include contraindications for renal impairment, severe liver disease, or metabolic acidosis, with caution advised in elderly patients or those on insulin/secretagogues due to hypoglycemia risk26. Common side effects include nasopharyngitis, diarrhea, and gastrointestinal discomfort16.
For patients already on metformin, treatment starts with 5 mg linagliptin combined with their current metformin dose (adjusted to match daily intake)1. The maximum daily metformin dose should not exceed 2000 mg, and renal/liver function must be monitored26. Drug interactions include reduced linagliptin efficacy with P-gp/CYP3A4 inducers (e.g., rifampin) and increased lactic acidosis risk with carbonic anhydrase inhibitor
.webp)
.png)
.jpeg)
.jpg)
.jpg)
.jpeg)
.jpg)
.webp)
.jpg)
 100 IU 3 ML.webp)
.jpg)
.webp)
.jpeg)
.jpg)
.jpg)
.jpeg)
 400MG.jpg)
.jpg)
Change Language